- GenusPlus Group reported full-year results for the year ended 30 June 2026, with sales rising to A$1,281.07 million and net income to A$49.02 million, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year.
- The combination of rapid revenue expansion and improved earnings per share highlights a scaling business that is converting a larger project base into stronger profitability.
- We’ll now explore how this substantial jump in full-year revenue and earnings shapes GenusPlus Group’s existing investment narrative and risks.
Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
GenusPlus Group Investment Narrative Recap
To own GenusPlus Group today, you need to believe in its role as a core contractor for Australia’s power and communications buildout, with projects converting into consistent earnings. The FY26 jump in revenue to A$1,281.07 million and net income to A$49.02 million supports this execution story, but also sharpens focus on the short term risk that cost pressures or project delays could compress margins. On balance, this result reinforces rather than materially changing the near term catalyst of major grid and renewables work ramping up.
The most relevant recent announcement is the FY26 earnings release itself, which confirms both rapid revenue growth and higher basic EPS from continuing operations at A$0.2675. This sits alongside prior guidance that highlighted a strong order book and growing recurring revenue, and it helps investors connect the earlier narrative about “rewiring the nation” with actual financial delivery. How durable these earnings prove to be as competition and input costs evolve is where the next phase of the story lies.
Yet beneath the strong revenue and EPS headline, investors should also be aware of how rising fixed costs could interact with...
Read the full narrative on GenusPlus Group (it's free!)
GenusPlus Group's narrative projects A$2.4 billion revenue and A$140.1 million earnings by 2029. This requires 35.1% yearly revenue growth and a A$93.6 million earnings increase from A$46.5 million today.
Uncover how GenusPlus Group's forecasts yield a A$12.16 fair value, a 42% upside to its current price.
Exploring Other Perspectives
Before this result, the most optimistic analysts were assuming revenue could reach about A$2.6 billion with earnings of around A$155.6 million, which is far more upbeat than consensus. When you compare that to the current A$1,281.07 million and A$49.02 million outcome, it is clear expectations differ widely and may shift again as investors weigh how quickly GenusPlus can turn today’s order book into tomorrow’s margins.
Explore 4 other fair value estimates on GenusPlus Group - why the stock might be worth as much as 42% more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your GenusPlus Group research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free GenusPlus Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GenusPlus Group's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Uncover the next big thing with 54 elite penny stocks that balance risk and reward.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com